Condition: Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) · Pancreatic Ductal Adenocarcinoma (PDAC) · Hepatocellular Carcinoma (HCC) · Sponsor: Shenzhen Xinhe Biomedical
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with high-risk recurrent solid tumors after radical surgery. The main questions it aims to answer are: What medical problems do participants have when using the combined treatment? Does XH001 injection combined with standard adjuvant treatment induce a specific T-cell response, and can it prolong the patient's relapse-free survival?
This description comes directly from the study's public registry record.
Yi Zhang · 0086-18615536063 · yiz@neocura.net
Bo Liu · 0086-18101388626 · bliu@neocura.net
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
| Peking University Cancer Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07594964